Articles in this series provide an accessible discussion of a particular aspect of the process of turning ideas into drugs. The aim is to allow readers with limited knowledge of a given area to become familiar with the key concepts and techniques involved. Written by those closely involved in the discovery process, these articles aim to provide insights that will aid in future drug discovery programs.
Index
2009
Advance online publication 9 October 2009
The future of drug development: advancing clinical trial design
John Orloff, Frank Douglas, Jose Pinheiro, Susan Levinson, Michael Branson, Pravin Chaturvedi, Ene Ette, Paul Gallo, Gigi Hirsch, Cyrus Mehta, Nitin Patel, Sameer Sabir, Stacy Springs, Donald Stanski, Matthias R. Evers, Edd Fleming, Navjot Singh, Tony Tramontin & Howard Golub
doi:10.1038/nrd3002
October 2009 Vol 8 No 10
New approaches to drug safety: a pharmacovigilance tool kit
Lesley Wise, John Parkinson, June Raine & Alasdair Breckenridge
p779 | doi:10.1038/nrd3002
July 2009 Vol 8 No 7
Multi–arameter phenotypic profiling: using cellular effects to characterize small–molecule compounds
Yan Feng, Timothy J. Mitchison, Andreas Bender, Daniel W. Young and John A. Tallarico
p567 | doi:10.1038/nrd2876
2008
November 2008 Vol 7 No 11
Typical pitfalls in applications for marketing authorization of biotechnological products in Europe
Christian K. Schneider & Gabriele Schäffner–Dallmann
839 doi:10.1038/nrd2728
April 2008 Vol 7 No 4
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology
John Dunlop, Mark Bowlby, Ravikumar Peri, Dmytro Vasilyev & Robert Arias
358 doi:10.1038/nrd2552
January 2008 Vol 7 No 1
Protein therapeutics: a summary and pharmacological classification
Benjamin Leader, Quentin J. Baca & David E. Golan
21 doi:10.1038/nrd2399
2007
August 2007 Vol 6 No 8
The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates
Jeffrey A. Kramer, John E. Sagartz and Dale L. Morris
p636 | doi:10.1038/nrd2378
2006
January 2006 Vol 5 No 1
Bayesian clinical trials
Donald A. Berry
p27 | doi:10.1038/nrd1927
2005
February 2005 Vol 4 No 2
Pricing medicines: theory and practice, challenges and opportunities
Nigel Gregson, Keiron Sparrowhawk, Josephine Mauskopf & John Paul
p121 | doi:10.1038/nrd1633
2004
October 2004 Vol 3 No 10
The role of the medicinal chemist in drug discovery - then and now
Joseph G. Lombardino & John A. Lowe
p853 | doi:10.1038/nrd1523
2003
November 2003 Vol 2 No 11
Virtual drug discovery and development for neglected diseases through public-private partnerships
Solomon Nwaka & Robert G. Ridley
p919 | doi:10.1038/nrd1230
October 2003 Vol 2 No 10
Protecting your inventions: the patent system
Philip M. Webber
p823 | doi:10.1038/nrd1200
September 2003 Vol 2 No 9
Trends in development and approval times for new therapeutics in the United States
Janice M. Reichert
p695 | doi:10.1038/nrd1178
August 2003 Vol 2 No 8
Logistics of process r&d: transforming laboratory methods to manufacturing scale
Hans-J�rgen Federsel
p654 | doi:10.1038/nrd1154
July 2003 Vol 2 No 7
Making better drugs: decision gates in non-clinical drug development
J. Fred Pritchard, Malle Jurima-Romet, Mark L. J. Reimer, Elisabeth Mortimer, Brenda Rolfe & Mitchell N. Cayen
p542 | doi:10.1038/nrd1131
June 2003 Vol 2 No 6
Predicting therapeutic value in the lead optimization phase of drug discovery
Terry Kenakin
p426 | doi:10.1038/nrd1110
May 2003 Vol 2 No 5
Hit and lead generation: beyond high-throughput screening
Konrad H. Bleicher, Hans-Joachim B�hm, Klaus M�ller & Alexander I. Alanine
p369 | doi:10.1038/nrd1086
April 2003 Vol 2 No 4
Designing screens: how to make your hits a hit
W. Patrick Walters & Mark Namchuk
p259 | doi:10.1038/nrd1063
March 2003 Vol 2 No 3
Combinatorial compound libraries for drug discovery: an ongoing challenge
H. Mario Geysen, Frank Schoenen, David Wagner & Richard Wagner
p222 | doi:10.1038/nrd1035
February 2003 Vol 2 No 2
Modern biomedical research: an internally self-consistent universe with little contact with medical reality?
David F. Horrobin
p151 | doi:10.1038/nrd1012
January 2003 Vol 2 No 1
Target selection in drug discovery
Jonathan Knowles and Gianni Gromo
p63 | doi:10.1038/nrd986
